GlassScriptPhysician profile
Gorden Yao
NPI 1043897721
$2,576.27
in general payments reported to CMS, 2019-2025
16 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $338 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Consulting Fee: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.77 |
| Consulting Fee | $637.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $940.95 | 2024-2025 | Pyrukynd |
| Astrazeneca Pharmaceuticals LP | $424.11 | 2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $367.76 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $327.48 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $142.16 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $89.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.94 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Vivus LLC | $47.15 | 2025 | Pancreaze |
| Almatica Pharma LLC | $28.71 | 2025 | Loreev Xr |
| Ardelyx, INC. | $26.53 | 2024 | Ibsrela |
| Amgen INC. | $25.45 | 2025 | Evenity |
| Exact Sciences Corporation | $22.79 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.83 | 2025 | Jardiance |
| Radius Health, INC. | $19.78 | 2025 | Tymlos |
| Azurity Pharmaceuticals, INC. | $18.62 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.80 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gorden Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.